CUE
Price
$0.66
Change
+$0.06 (+10.00%)
Updated
May 23 closing price
Capitalization
49.84M
106 days until earnings call
INAB
Price
$0.14
Change
+$0.01 (+7.69%)
Updated
May 23 closing price
Capitalization
13.15M
74 days until earnings call
Interact to see
Advertisement

CUE vs INAB

Header iconCUE vs INAB Comparison
Open Charts CUE vs INABBanner chart's image
Cue Biopharma
Price$0.66
Change+$0.06 (+10.00%)
Volume$307.03K
Capitalization49.84M
IN8bio
Price$0.14
Change+$0.01 (+7.69%)
Volume$2.64M
Capitalization13.15M
CUE vs INAB Comparison Chart
Loading...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CUE vs. INAB commentary
May 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a Hold and INAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 26, 2025
Stock price -- (CUE: $0.66 vs. INAB: $0.14)
Brand notoriety: CUE and INAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CUE: 191% vs. INAB: 213%
Market capitalization -- CUE: $49.84M vs. INAB: $13.15M
CUE [@Biotechnology] is valued at $49.84M. INAB’s [@Biotechnology] market capitalization is $13.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CUE’s FA Score shows that 0 FA rating(s) are green whileINAB’s FA Score has 1 green FA rating(s).

  • CUE’s FA Score: 0 green, 5 red.
  • INAB’s FA Score: 1 green, 4 red.
According to our system of comparison, INAB is a better buy in the long-term than CUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CUE’s TA Score shows that 4 TA indicator(s) are bullish while INAB’s TA Score has 4 bullish TA indicator(s).

  • CUE’s TA Score: 4 bullish, 5 bearish.
  • INAB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INAB is a better buy in the short-term than CUE.

Price Growth

CUE (@Biotechnology) experienced а -8.76% price change this week, while INAB (@Biotechnology) price change was +12.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

CUE is expected to report earnings on Sep 08, 2025.

INAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CUE($49.8M) has a higher market cap than INAB($13.2M). CUE YTD gains are higher at: -39.321 vs. INAB (-43.663). INAB has higher annual earnings (EBITDA): -23.92M vs. CUE (-40.02M). CUE has more cash in the bank: 32.4M vs. INAB (11.9M). INAB has less debt than CUE: INAB (4.27M) vs CUE (9.51M). CUE has higher revenues than INAB: CUE (9.53M) vs INAB (0).
CUEINABCUE / INAB
Capitalization49.8M13.2M377%
EBITDA-40.02M-23.92M167%
Gain YTD-39.321-43.66390%
P/E RatioN/AN/A-
Revenue9.53M0-
Total Cash32.4M11.9M272%
Total Debt9.51M4.27M223%
FUNDAMENTALS RATINGS
CUE: Fundamental Ratings
CUE
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CUEINAB
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 21 days ago
77%
Bullish Trend 18 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTMX2.230.10
+4.69%
CytomX Therapeutics
MCK716.095.45
+0.77%
McKesson Corp
NWBI12.17-0.07
-0.57%
Northwest Bancshares
PODC2.04-0.08
-3.77%
PodcastOne
DV13.13-0.56
-4.09%
DoubleVerify Holdings

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with DNLI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
+10.01%
DNLI - CUE
39%
Loosely correlated
-1.76%
SGMT - CUE
37%
Loosely correlated
+1.17%
VCYT - CUE
36%
Loosely correlated
-1.63%
OCS - CUE
33%
Loosely correlated
+5.91%
AXON - CUE
33%
Loosely correlated
-0.55%
More

INAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INAB has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INAB jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INAB
1D Price
Change %
INAB100%
+15.00%
IDYA - INAB
47%
Loosely correlated
-1.72%
GRI - INAB
36%
Loosely correlated
-13.04%
SNSE - INAB
35%
Loosely correlated
-1.34%
CUE - INAB
32%
Poorly correlated
+10.01%
SRZN - INAB
28%
Poorly correlated
-2.16%
More